Why Keryx Biopharmaceuticals, Yongye International, and Five Below Are Today's 3 Best Stocks

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Is anyone really shocked that we were once again presented with mixed economic data that pressured the broad-based S&P 500 (SNPINDEX: ^GSPC  ) throughout the latter half of the trading day?

On the bright side, durable goods orders jumped 2.2% in February, the best showing since November, and reversing a two-month decline. The biggest boost came from airline and defense orders which rose 13.6% and 13.5%, respectively. Automotive and auto parts also jumped 3.6%. A continued upward trend for these larger products would bode well for the ongoing U.S. economic recovery.

The other side of the coin from the Mortgage Bankers Association showed a 3.5% decline in weekly loan originations. As the Federal Reserve winds down its quantitative-easing economic stimulus it's possible that fewer long-term U.S. Treasury purchases could push long-term lending rates higher. If that were to happen, given how fickle the U.S. consumer has been about refinancing and purchasing a home anytime interest rates tick even modestly higher, it could put a serious dent into the housing and banking sectors.

By day's end investors digested this mixed data and ultimately pushed the S&P 500 lower by 13.06 points (-0.70%) to close at 1,852.56.

Negativity certainly wasn't the name of the game for clinical-stage biopharma Keryx Biopharmaceuticals (NASDAQ: KERX  ) , which surged 17.4% on the day. Although no readily apparent news was available, it appears the stock soared on a rumor, as reported by, that the Centers for Medicare and Medicaid Services may delay its decision to move oral-only end-stage renal disease drugs into the ESRD bundle until 2024. If this rumor proves true, it could allow for itemized payments of select medications through Medicare Part D throughout the next decade, including drugs related to dialysis treatments such as Keryx's Zerenex. It would certainly be good news if true, but playing the rumor game can be very dangerous in an already volatile sector. I would suggest taking today's move with a gigantic grain of salt.

China-based crop and animal nutrients supplier Yongye International (NASDAQ: YONG  ) also roared higher by 13.3% after the company announced today in an SEC filing that a consortium of buyers including Full Alliance International had, via electronic mail, boosted its going-private offer by 4.6% to $7 per share from $6.69. The previous offer failed to win approval from the majority of shareholders, so investors are clearly excited that this latest private buyout offer may end in success. However, I see very limited upside (less than 4% based on today's close) and considerable downside if Yongye's shareholders again reject this deal. That looks like a reasonable reason to keep your distance.

Finally, specialty value retailer Five Below (NASDAQ: FIVE  ) advanced 11.4% after it reported better than expected fourth-quarter results. For the quarter, Five Below reported a 22% increase in revenue to $212 million, while earnings per share jumped to $0.47. Wall Street had only expected $207.9 million in sales on $0.45 in EPS. Looking ahead, Five Below matched the Street's fiscal 2015 forecast with its full-year revenue range of $672 million-$678 million on EPS of $0.86-$0.89. While investors seem quite pleased with today's results, I'm a bit worried about its paltry 0.3% increase in comparable-store sales. Such weak organic growth isn't worth 37 times forward earnings, in my opinion.

Keryx, Yongye, and Five Below all rocketed higher today, but all three could struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 26, 2014, at 6:44 PM, Scott63 wrote:

    I don't think the amount of volume reflects buying on a questionable rumor. Now with a 25-30% short position in the stock, that could have heated things up today. Of course the run may have brought the shorts back in or will bring them back in if they see the same risk tomorrow they saw before.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2891923, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:32:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,512.56 161.18 0.99%
S&P 500 1,969.25 20.39 1.05%
NASD 4,790.11 40.13 0.84%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 11:22 AM
^GSPC $1968.43 Up +19.57 +1.00%
S&P 500 INDEX CAPS Rating: No stars
FIVE $34.98 Down -3.03 -7.97%
Five Below CAPS Rating: **
KERX $5.48 Down -0.55 -9.12%
Keryx Biopharmaceu… CAPS Rating: **
YONG $0.00 Down +0.00 +0.00%
Yongye Internation… CAPS Rating: **